Trillium Therapeutics Inc (TRIL.CA) Stock Fundamental Analysis

TSX:TRIL

23.33
+0.11 (+0.47%)
Last: Nov 19, 2021, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

2

Overall TRIL gets a fundamental rating of 2 out of 10. We evaluated TRIL against 23 industry peers in the Biotechnology industry. The financial health of TRIL is average, but there are quite some concerns on its profitability. TRIL does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • TRIL had negative earnings in the past year.
TRIL.CA Yearly Net Income VS EBIT VS OCF VS FCFTRIL.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 -20M -40M -60M

1.2 Ratios

Industry RankSector Rank
ROA -21.06%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
TRIL.CA Yearly ROA, ROE, ROICTRIL.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 0 1K 2K 3K 4K

1.3 Margins

  • TRIL does not have Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) -139737.5%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TRIL.CA Yearly Profit, Operating, Gross MarginsTRIL.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 -10K -20K -30K -40K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. Health

2.1 Basic Checks

  • Compared to 1 year ago, TRIL has more shares outstanding
  • TRIL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
TRIL.CA Yearly Shares OutstandingTRIL.CA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 20M 40M 60M 80M 100M
TRIL.CA Yearly Total Debt VS Total AssetsTRIL.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 100M 200M 300M

2.2 Solvency

  • An Altman-Z score of 50.66 indicates that TRIL is not in any danger for bankruptcy at the moment.
  • TRIL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 50.66
ROIC/WACCN/A
WACCN/A
TRIL.CA Yearly LT Debt VS Equity VS FCFTRIL.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 0 100M 200M

2.3 Liquidity

  • A Current Ratio of 12.04 indicates that TRIL has no problem at all paying its short term obligations.
  • A Quick Ratio of 12.04 indicates that TRIL has no problem at all paying its short term obligations.
Industry RankSector Rank
Current Ratio 12.04
Quick Ratio 12.04
TRIL.CA Yearly Current Assets VS Current LiabilitesTRIL.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 50M 100M 150M 200M 250M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. Growth

3.1 Past

  • TRIL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 52.93%, which is quite impressive.
  • The Revenue for TRIL has decreased by -66.67% in the past year. This is quite bad
EPS 1Y (TTM)52.93%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-29.33%
Revenue 1Y (TTM)-66.67%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • TRIL is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -1.32% yearly.
  • The Revenue is expected to decrease by -14.87% on average over the next years. This is quite bad
EPS Next Y-9.05%
EPS Next 2Y-2.87%
EPS Next 3Y-1.35%
EPS Next 5Y-1.32%
Revenue Next Year-96.9%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%

3.3 Evolution

TRIL.CA Yearly Revenue VS EstimatesTRIL.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 50K 100K 150K
TRIL.CA Yearly EPS VS EstimatesTRIL.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -1 -2 -3 -4

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for TRIL. In the last year negative earnings were reported.
  • Also next year TRIL is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TRIL.CA Price Earnings VS Forward Price EarningsTRIL.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 -20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -29.17
TRIL.CA Per share dataTRIL.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-2.87%
EPS Next 3Y-1.35%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • TRIL does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

Trillium Therapeutics Inc

TSX:TRIL (11/19/2021, 7:00:00 PM)

23.33

+0.11 (+0.47%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)N/A
Earnings (Next)N/A
Inst Owners30.26%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap2.45B
Revenue(TTM)40.00K
Net Income(TTM)-55.90M
Analysts78
Price Target18.87 (-19.12%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 47962.91
P/FCF N/A
P/OCF N/A
P/B 7.89
P/tB N/A
EV/EBITDA -29.17
EPS(TTM)-1.01
EYN/A
EPS(NY)-1.07
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0
BVpS2.96
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -21.06%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) -139737.5%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y0%
ROICexgc growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 12.04
Quick Ratio 12.04
Altman-Z 50.66
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)52.93%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-29.33%
EPS Next Y-9.05%
EPS Next 2Y-2.87%
EPS Next 3Y-1.35%
EPS Next 5Y-1.32%
Revenue 1Y (TTM)-66.67%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-96.9%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A

Trillium Therapeutics Inc / TRIL.CA FAQ

What is the ChartMill fundamental rating of Trillium Therapeutics Inc (TRIL.CA) stock?

ChartMill assigns a fundamental rating of 3 / 10 to TRIL.CA.


Can you provide the valuation status for Trillium Therapeutics Inc?

ChartMill assigns a valuation rating of 1 / 10 to Trillium Therapeutics Inc (TRIL.CA). This can be considered as Overvalued.


Can you provide the profitability details for Trillium Therapeutics Inc?

Trillium Therapeutics Inc (TRIL.CA) has a profitability rating of 3 / 10.


What is the earnings growth outlook for Trillium Therapeutics Inc?

The Earnings per Share (EPS) of Trillium Therapeutics Inc (TRIL.CA) is expected to decline by -9.05% in the next year.